|Articles|June 14, 2007

A new day in preventing meningococcal disease: Sizing up the available vaccines

The new conjugate vaccine MCV4 promises longer duration of immunity and, perhaps, greater clinical efficacy than the polysaccharide vaccine MPSV4. Questions remain about booster doses, vaccinating young children, and safety.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!

Related Content

Latest CME

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis
Multimedia

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Jeffrey A. Sparks, MD, MMSc

View more
Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis
Multimedia

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Frank B. Cortazar, MD; Lindsay S. Lally, MD

View more
Burst CME: Targeted Therapy for Optimal Psoriasis Management
Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

View more
Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management
Video

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

View more
Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update
Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

View more
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us